Relationship Graph Explorer
Follow the connections
Every herb, ingredient, formula, gene target, and disease — connected through real research. Search, pick a subject, and navigate the graph in any direction.
🌿
Herb
6,826
→
⚗️
Ingredient
44,598
→
🧬
Gene Target
15,695
→
🏥
Disease
30,467
→
🧪
Evidence
23,295
trials · metas · refs
Plus 6,743 TCM formulas connecting herbs together
⚗️ Ingredient
Heparin
15
Clinical Trials
139
Meta-Analyses
0
PubMed References
Top Conditions Studied with Heparin
COVID-19. 2
The Cochrane Peripheral Vascular Diseases Group 2
The Cochrane Neonatal Group 2
Port occlusion is a common complication. Maintaining the pat 2
COVID-19 2
Sepsis, severe sepsis, septic shock or with disseminated int 1
hypertriglyceridemic pancreatitis 1
Coronary artery disease is still the most common cause of de 1
Stroke 1
Venous thromboembolism, including deep veins thrombolism(DVT 1
Pre-eclampsia (defined as the presence of high blood pressur 1
Fetal growth restriction (FGR), also known as intrauterine g 1
📋 Sample Trials
NCT05224388
Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels.
Completed
NCT05621915
Nadroparin Pharmacokinetics in Different Stages of COVID-19
Completed
NCT05184101
Inhaled Heparin for Hospitalised Patients With Coronavirus Disease 2019 (COVID-19)
Withdrawn · Phase 2|Phase 3
📊 Sample Meta-Analyses
CRD42015026534
Heparin for the prevention of intraventricular hemorrhage in very preterm infants [Cochrane Protocol]
The Cochrane Neonatal Group
CRD42019132615
The comparative efficacy and safety of novel oral anticoagulants, warfarin and low molecular weight heparin in patients with cancer to prevent venous thromboembolism: a network meta-analysis
The safety and efficacy of direct oral anticoagulants in cancer patients is curr
CRD42016040012
Use of heparin bonded grafts in angioaccess: a review and meta analysis
Arteriovenous grafts used in hemodialysis patients are offered as a second line
📚 Sample References
None linked yet.
⚗️ All Ingredient data fields for Heparin
⚗️ Identity
Name
Heparin
🧪 Chemistry
Molecular Weight
591.4560
LogP
-8.6131
Drug-likeness
0.116
H-Bond Acceptors
20
H-Bond Donors
5
Rotatable Bonds
10
🔬 Structures
Canonical SMILES
C(C1C(C(C(C(O1)O)NS(=O)(=O)[O-])O)OC2C(C(C(C(O2)C(=O)[O-])O)O)OS(=O)(=O)[O-])OS(=O)(=O)[O-]
Isomeric SMILES
C([C@@H]1C([C@@H](C(C(O1)O)NS(=O)(=O)[O-])O)O[C@H]2C([C@H](C(C(O2)C(=O)[O-])O)O)OS(=O)(=O)[O-])OS(=O)(=O)[O-]
InChIKey
OHJKXVLJWUPWQG-IUYNYSEKSA-J
InChI
InChI=1S/C12H21NO20S3/c14-4-3(13-34(20,21)22)11(19)30-2(1-29-35(23,24)25)7(4)31-12-9(33-36(26,27)28)6(16)5(15)8(32-12)10(17)18/h2-9,11-16,19H,1H2,(H,17,18)(H,20,21,22)(H,23,24,25)(H,26,27,28)/p-4/t2-,3?,4-,5?,6+,7?,8?,9?,11?,12-/m1/s1
🔗 External References
🔍 Raw view — every non-empty column on this row (29 fields)
name
Heparin
herb ingredient id
HBIN029056
canonical smiles
C(C1C(C(C(C(O1)O)NS(=O)(=O)[O-])O)OC2C(C(C(C(O2)C(=O)[O-])O)O)OS(=O)(=O)[O-])OS(=O)(=O)[O-]
isomeric smiles
C([C@@H]1C([C@@H](C(C(O1)O)NS(=O)(=O)[O-])O)O[C@H]2C([C@H](C(C(O2)C(=O)[O-])O)O)OS(=O)(=O)[O-])OS(=O)(=O)[O-]
inchi
InChI=1S/C12H21NO20S3/c14-4-3(13-34(20,21)22)11(19)30-2(1-29-35(23,24)25)7(4)31-12-9(33-36(26,27)28)6(16)5(15)8(32-12)10(17)18/h2-9,11-16,19H,1H2,(H,17,18)(H,20,21,22)(H,23,24,25)(H,26,27,28)/p-4/t2-,3?,4-,5?,6+,7?,8?,9?,11?,12-/m1/s1
inchikey
OHJKXVLJWUPWQG-IUYNYSEKSA-J
mol wt
591.4560
num h acceptors
20
num h donors
5
mol logp
-8.6131
num rotatable bonds
10
drug likeness
0.116
tcmid ingredient id
23072; 23068
tcm id ingredient id
3788
pubchem cid
25244225
npass id
NPC99005
hit id
C0969
🏥 Linked Health Topics
2 · diseases via target pathways📋 Clinical Trials
12 · subject of clinical studyNCT05224388 Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular
→ COVID-19|Deep Vein Thrombosis|Anticoagulants and B
NCT05621915 Nadroparin Pharmacokinetics in Different Stages of COVID-19
→ Thrombosis|Nadroparin|COVID-19|Mechanical Ventilat
NCT05184101 Inhaled Heparin for Hospitalised Patients With Coronavirus Disease 2019 (COVID-1
→ COVID-19
NCT05329155 Early Administration of Heparin at FMC for PPCI of STEMI Patients
→ STEMI|Primary PCI
NCT05509647 Unfractionated Heparin in COVID-19 and Non-COVID-19 Patients
→ Heparin Overdose of Undetermined Intent|COVID-19
NCT05204550 Intranasal Heparin Treatment to Reduce Transmission Among Household Contacts of
→ COVID-19
NCT05257213 Heparin Solution Versus Anti-adhesion Barrier Gel for Intrauterine Adhesions Pre
→ Intrauterine Adhesion
NCT05178550 A Study in Healthy Participants Investigating Biomarkers After Exposure to Hepar
→ Healthy Volunteers
NCT05191290 Comparison of Biocompatibility of Plasmapheresis Procedures With Citrate and Hep
→ Apheresis|Anticoagulation
NCT05188339 The Effectiveness and Safety of 4% Sodium Citrate as a Lock Solution in Central
→ Central Venous Catheter Thrombosis|Renal Dialysis
NCT06076434 Low-Molecular-Weight Heparin Injection in Stroke Patients
→ Stroke
NCT05737121 Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidoc
→ Interstitial Cystitis|Bladder Pain Syndrome
📊 Meta-Analyses
12 · systematic reviewCRD42015026534 Heparin for the prevention of intraventricular hemorrhage in very preterm infant
→ The Cochrane Neonatal Group
CRD42019132615 The comparative efficacy and safety of novel oral anticoagulants, warfarin and l
→ The safety and efficacy of direct oral anticoagula
CRD42016040012 Use of heparin bonded grafts in angioaccess: a review and meta analysis
→ Arteriovenous grafts used in hemodialysis patients
CRD42016043754 Efficacy and safety of bivalirudin versus heparin plus routine use of GP Ilb/III
→ Antithrombotic therapy is essential to prevent adv
CRD42018084248 Aspirin and heparin for the prevention of preeclampsia: a systematic review and
→ Around the world, preeclampsia (PE) is still one o
CRD42018092372 Low-molecular-weight heparin for the prevention and treatment of hypertensive di
→ Hypertensive disorders during pregnancy are a grou
CRD42020205574 A systematic review and meta-analysis on the therapeutic efficacy of heparin and
CRD42020207474 Low-molecular-weight heparin for the prevention of preeclampsia in high risk wom
→ Pre-eclampsia (PE), which affects 3–5% of pregnanc
CRD42021250656 Low molecular weight heparin and pregnancy outcomes in women with inherited thro
→ Inherited thrombophilia as a genetic disease can i
CRD42021278496 Factor Xa inhibitors and low molecular weight heparins for the perioperative sur
→ VTE is a leading cause of preventable death in pat
CRD42021279624 A systematic review and meta-analysis of the safety of unfractionated heparin an
→ COVID-19.
CRD42021283651 Efficacy of therapeutic versus prophylactic dose of heparin for thromboprophylax
→ Thromboembolic disease, including venous thromboem
How relationships are computed
- Clinical Trials / Meta-Analyses / References: direct foreign-key link via
subject_entity_id(Phase 2d wireup) - Formula ↔ Herbs: text bridge via
formulas.herbs_in_pinyinmatchingherbs.pinyin_name - Herb ↔ Ingredient:
ACTIVE — direct link via
herb_ingredients - Ingredient ↔ Target:
ACTIVE — direct link via
ingredient_targets - Target ↔ Disease:
ACTIVE — direct link via
target_health_topics - Herb → Target → Disease (full chemical spine): ACTIVE — joins all three link tables